M.M. Hojieva ^1,2

1. State Institution «Republican Cancer Research Center» of the Ministry of Health and Social Protection of the Population, Dushanbe, Republic of Tajikistan;
2. State educational institution «Institute of Postgraduate Education in Healthcare of the Republic of Tajikistan,» Dushanbe, Republic of Tajikistan

DOI: https://www.doi.org/10.52532/2663-4864-2023-3-69-59-64

UDC: 618.11:616-006.66-033.2:615.032

Year: 2023 issure: 69 number: 3 pages: 59-64

Download PDF:

ABSTRACT

Relevance: Ovarian cancer is the most aggressive form among all nosologies of the female reproductive system. More than 75% of women are diagnosed at advanced stages, and about 60% have metastases to other organs at diagnosis. Systemic chemotherapy has a limited effect on the peritoneum and a high incidence of side effects. There is a need for more effective approaches to prolong survival and preserve quality of life by reducing disease symptoms and treatment side effects, especially in countries with limited health resources.
The study aimed to evaluate the preliminary results of using pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with ovarian cancer with peritoneal metastases.
Methods: 18 women with disease stage T3a-cN0M0 treated at the Republican Cancer Research Center for 2022-2023 were studied. The first group included six patients who underwent cytoreduction + PIPAC at the 1st stage, and the second group (12 women) underwent exploratory laparotomy + biopsy + PIPAC at the 1st stage. Patients in both groups received two courses of chemotherapy followed by a repeat of PIPAC. Taxanes + platinum-containing drugs were used in the PIPAC process – cisplatin or carboplatin with doxorubicin. Each patient received 2 PIPAC sessions and 4 to 6 chemotherapy courses with cytoreductive surgery. All patients underwent laparoscopic control with a reassessment of the Peritoneal Carcinomatosis Index (PCI) by Sugarbaker (2010) and repeated biopsy of the peritoneum.
Results: The use of cytoreductive surgery + PIPAC at the first stage made it possible to level the symptoms of peritoneal carcinomatosis, to achieve a complete radiological response in 12 (67%) cases, a complete morphological response in the form of complete regression in 44%, a moderate response in 39% of cases
Conclusion: The use of PIPAC with a cytoreductive component at the first stage of combined treatment of ovarian cancer with peritoneal metastases improves immediate results and patient’s quality of life and reduces the hospital stay. The research is ongoing.
Keywords: pressurized intraperitoneal aerosol chemotherapy (PIPAC), ovarian cancer, peritoneal carcinomatosis.

List of sources used:

1. Thomakos N., Diakosavvas M., Machairiotis N., Fasoulakis Z., Zarogoulidis P., Rodolakis A. Rare distant metastatic disease of ovarian and peritoneal carcinomatosis: a review of the literature // Cancers (Basel). – 2019. – Vol. 11. – P. 1044. https://doi.org/10.3390/cancers11081044
2. Kukubasov E.K., Satanova A.R., Bolatbekova R.O., Kaldybekov D.B., Kurmanova A.A., Bertleuov O.O. Jepidemiologija raka jaichnikov v Kazahstane (2013-2018 gody) // Onkologija i radiologija Kazahstana. – 2020. – №56(2). – S. 9-11 [Kukubasov E.K., Satanova A.R., Bolatbekova R.O., Kaldybekov D.B., Kurmanova A.A., Bertleuov O.O. Epidemiology of ovarian cancer in Kazakhstan (2013-2018) // Oncology and radiology of Kazakhstan. – 2020. – No. 56(2). – P. 9-11 (in Russ.)]. https://doi.org/10.52532/2521-6414-2020-2-56-9-11
3. Anwar A., Kasi A. Peritoneal Cancer. – Treasure Island (FL): StatPearls Publishing, 2023. https://www.ncbi.nlm.nih.gov/books/NBK562138/
4. Zaharenko A.A., Natha A.S., Beljaev M.A., Trushin A.A., Zajcev D.A., Ten O.A., Koval’chuk Ju.P., Bljum N.M., Jakovleva M.V., Bagnenko S.F. Jeksperimental’noe obosnovanie maksimal’no jeffektivnogo rezhima laparoskopicheskoj ajerozol’noj vnutribrjushinnoj himioterapii (PIPAC) // Vopr. Onkol. – 2017. – №63(3). – S. 490-496 [Zakharenko A.A., Natha A.S., Belyaev M.A., Trushin A.A., Zaitsev D.A., Ten O.A., Kovalchuk Yu.P., Blum N.M., Yakovleva M. .V., Bagnenko S.F. Experimental substantiation of the most effective regimen of laparoscopic aerosol intraperitoneal chemotherapy (PIPAC) // Issues. Oncol. – 2017. – No. 63(3). – P. 490-496 (in Russ.)]. https://cyberleninka.ru/article/n/eksperimentalnoe-obosnovanie-maksimalno-effektivnogo-rezhima-laparoskopicheskoy-aerozolnoy-vnutribryushinnoy-himioterapii-pipac
5. Zaharenko A.A., Beljaev M.A., Vervekin I.V., Bagnenko S.F. Primenenie metoda intraoperacionnoj vnutribrjushinnoj ajerozol’noj himioterapii (PIPAC) v kompleksnom lechenii mestnorasprostranennogo raka zheludka s citologicheski-negativnymi smyvami s brjushiny: protokol klinicheskogo issledovanija GASPACCO // Vopr. Onkol. – 2022. – №68(6). – S. 733-740 [Zakharenko A.A., Belyaev M.A., Vervekin I.V., Bagnenko S.F. Application of intraoperative intraperitoneal aerosol chemotherapy (PIPAC) in the complex treatment of locally advanced gastric cancer with cytologically negative peritoneal washings: protocol for the GASPACCO clinical trial // Issues. Oncol. – 2022. – No. 68(6). – P. 733-740 (in Russ.)]. https://cyberleninka.ru/article/n/primenenie-metoda-intraoperatsionnoy-vnutribryushinnoy-aerozolnoy-himioterapii-pipac-v-kompleksnom-lechenii-mestnorasprostranennogo
6. Somashekhar S.P., Ashwin K.R., Rauthan A., Rohit K.C. Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer – study protocol for a randomized control trial // Pleura Peritoneum. – 2019. – No. 4(1). – P. 20180111. https://doi.org/10.1515/pp-2018-0111
7. Mohammad A., Hor M., Baradeiya A.M., Qasim H., Nasr M. Is Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) Effective in Ovarian Cancer with Peritoneal Metastasis? // Cureus. – 2022. – No. 14(8). – P. 27837. https://doi.org/10.7759/cureus.27837
8. Graversen M., Detlefsen S., Asmussen J., Mahdi B., Fristrup C., Pfeiffer P., Mortensen M.B. Treatment of peritoneal carcinomatosis with Pressurized IntraPeritoneal Aerosol Chemotherapy – PIPAC-OPC2 // Pleura Peritoneum. – 2018. – No. 3(2). – P. 20180108. https://doi.org/10.1515/pp-2018-0108
9. Alyami M., Gagniere J., Sgarbura O., Cabelguenne D., Villeneuve L., Pezet D., Quenet F., Glehen O., Bakrin N., Passot G. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis // Eur. J. Surg. Oncol. – 2017. – No. 43(11). – P. 2178-2183. https://doi.org/10.1016/j.ejso.2017.09.010
10. Mercier F., Bakrin N., Bartlett D.L., Goere D., Quenet F., Dumont F., Heyd B., Abboud K., Marolho C., Villeneuve L., Glehen O.; PSOGI Working Group; BIG-RENAPE Working Group. Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE // Ann. Surg. Oncol. – 2018. – No. 25(6). – P. 1668-1675. https://doi.org/10.1245/s10434-018-6464-z
11. Somashekhar S.P., Ashwin K.R., Yethadka R., Zaveri S.S., Ahuja V.K., Rauthan A., Rohit K.C. Impact of extent of parietal peritonectomy on oncological outcome after cytoreductive surgery and HIPEC // Pleura Peritoneum. – 2019. – No. 4(4). – P. 20190015. https://doi.org/10.1515/pp-2019-0015
12. Sugarbaker P.H. Surgical responsibilities in the management of peritoneal carcinomatosis // J. Surg. Oncol. – 2010. – No. 101(8). – P. – 713-24. https://doi.org/10.1002/jso.21484